ImmunoPrecise Antibodies (IPA) Competitors $1.76 +0.13 (+7.98%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$1.73 -0.03 (-1.70%) As of 07:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPA vs. DSGN, VOR, ACIU, ESPR, PROK, KOD, SLS, LRMR, CRGX, and CYBNShould you be buying ImmunoPrecise Antibodies stock or one of its competitors? The main competitors of ImmunoPrecise Antibodies include Design Therapeutics (DSGN), Vor Biopharma (VOR), AC Immune (ACIU), Esperion Therapeutics (ESPR), ProKidney (PROK), Kodiak Sciences (KOD), SELLAS Life Sciences Group (SLS), Larimar Therapeutics (LRMR), CARGO Therapeutics (CRGX), and Cybin (CYBN). These companies are all part of the "pharmaceutical products" industry. ImmunoPrecise Antibodies vs. Its Competitors Design Therapeutics Vor Biopharma AC Immune Esperion Therapeutics ProKidney Kodiak Sciences SELLAS Life Sciences Group Larimar Therapeutics CARGO Therapeutics Cybin Design Therapeutics (NASDAQ:DSGN) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends. Which has more volatility and risk, DSGN or IPA? Design Therapeutics has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500. Comparatively, ImmunoPrecise Antibodies has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Do analysts rate DSGN or IPA? Design Therapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 9.89%. ImmunoPrecise Antibodies has a consensus target price of $4.00, suggesting a potential upside of 127.27%. Given ImmunoPrecise Antibodies' stronger consensus rating and higher possible upside, analysts plainly believe ImmunoPrecise Antibodies is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Design Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00ImmunoPrecise Antibodies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is DSGN or IPA more profitable? Design Therapeutics has a net margin of 0.00% compared to ImmunoPrecise Antibodies' net margin of -190.76%. Design Therapeutics' return on equity of -22.85% beat ImmunoPrecise Antibodies' return on equity.Company Net Margins Return on Equity Return on Assets Design TherapeuticsN/A -22.85% -22.02% ImmunoPrecise Antibodies -190.76%-88.87%-49.26% Do institutionals & insiders have more ownership in DSGN or IPA? 56.6% of Design Therapeutics shares are owned by institutional investors. Comparatively, 6.7% of ImmunoPrecise Antibodies shares are owned by institutional investors. 31.2% of Design Therapeutics shares are owned by insiders. Comparatively, 6.8% of ImmunoPrecise Antibodies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor DSGN or IPA? In the previous week, ImmunoPrecise Antibodies had 3 more articles in the media than Design Therapeutics. MarketBeat recorded 3 mentions for ImmunoPrecise Antibodies and 0 mentions for Design Therapeutics. ImmunoPrecise Antibodies' average media sentiment score of 0.68 beat Design Therapeutics' score of 0.00 indicating that ImmunoPrecise Antibodies is being referred to more favorably in the news media. Company Overall Sentiment Design Therapeutics Neutral ImmunoPrecise Antibodies Positive Which has stronger earnings & valuation, DSGN or IPA? ImmunoPrecise Antibodies has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than ImmunoPrecise Antibodies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDesign TherapeuticsN/AN/A-$49.59M-$0.99-3.68ImmunoPrecise Antibodies$18.16M4.43-$20.13M-$1.16-1.52 SummaryImmunoPrecise Antibodies beats Design Therapeutics on 8 of the 15 factors compared between the two stocks. Get ImmunoPrecise Antibodies News Delivered to You Automatically Sign up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPA vs. The Competition Export to ExcelMetricImmunoPrecise AntibodiesMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$74.60M$1.97B$5.47B$8.95BDividend YieldN/AN/A5.25%4.04%P/E Ratio-1.5235.7726.9920.11Price / Sales4.4311.18428.71119.81Price / CashN/A54.5536.8257.86Price / Book1.898.567.985.56Net Income-$20.13M-$62.39M$3.16B$248.40M7 Day Performance66.04%4.26%2.38%4.67%1 Month Performance162.77%4.34%2.17%6.64%1 Year Performance77.78%9.18%33.81%21.31% ImmunoPrecise Antibodies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPAImmunoPrecise Antibodies2.528 of 5 stars$1.76+8.0%$4.00+127.3%+76.0%$74.60M$18.16M-1.5280News CoverageDSGNDesign Therapeutics0.3745 of 5 stars$3.37-5.6%$4.00+18.7%+4.0%$202.66MN/A-3.4040Positive NewsVORVor Biopharma3.9425 of 5 stars$1.62+52.8%$5.63+247.4%+164.9%$202.44MN/A-0.98140Options VolumeGap UpHigh Trading VolumeACIUAC Immune2.7562 of 5 stars$2.03+1.0%$12.00+491.1%-40.5%$201.82M$31.02M-3.50140ESPREsperion Therapeutics4.2296 of 5 stars$0.98-0.9%$7.00+611.1%-51.3%$196.93M$332.31M-1.23200Positive NewsPROKProKidney0.7394 of 5 stars$0.59-11.5%$3.50+491.1%+68.8%$195.73M$80K-0.993Trending NewsGap UpHigh Trading VolumeKODKodiak Sciences4.1301 of 5 stars$3.73+0.8%$9.00+141.3%+58.5%$195.23MN/A-1.0390News CoverageSLSSELLAS Life Sciences Group0.1249 of 5 stars$2.19+12.3%N/A+77.9%$194.57M$1M-5.7610High Trading VolumeLRMRLarimar Therapeutics1.9094 of 5 stars$2.89-4.6%$18.50+540.1%-59.5%$194.01MN/A-1.9430CRGXCARGO Therapeutics2.1148 of 5 stars$4.12-1.7%$15.00+264.1%-71.4%$193.20MN/A-0.89116Trending NewsAnalyst ForecastGap UpCYBNCybin2.9153 of 5 stars$8.39+2.9%$86.00+925.0%N/A$193.17MN/A-1.9250News CoverageAnalyst Forecast Related Companies and Tools Related Companies Design Therapeutics Alternatives Vor Biopharma Alternatives AC Immune Alternatives Esperion Therapeutics Alternatives ProKidney Alternatives Kodiak Sciences Alternatives SELLAS Life Sciences Group Alternatives Larimar Therapeutics Alternatives CARGO Therapeutics Alternatives Cybin Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPA) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoPrecise Antibodies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunoPrecise Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
